Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07872046 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study on the Impact of Recombinant Zoster Vaccine on Major Adverse Cardiovascular Events in Adults >=50 Years of Age With Established Cardiovascular Disease or With >=2 Cardiovascular Risk Factors

StatusNot Yet Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
GlaxoSmithKline
246 trials monitored
See 20 trials at risk
Heart Disease
8,786 trials monitored
See 412 trials at risk
This study aims to evaluate the effect of the recombinant zoster vaccine (RZV) on the occurrence of clinically important cardiovascular (heart and blood vessel) events, with a focus on major adverse cardiovascular events (MACE), in adults with established cardiovascular disease (CVD) or with 2 or more CV risk factors. Participants will be randomized to receive either RZV or placebo.
Trial Details
NCT Number NCT07872046
Lead Sponsor GlaxoSmithKline
Conditions
(from sponsor)		 Cardiovascular Disease
Related terms Cardiovascular Diseases
Enrollment 16,390 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov